

SB 465-FN - AS AMENDED BY THE SENATE

03/05/2026 0842s

2026 SESSION

26-2002

09/05

SENATE BILL **465-FN**

AN ACT classifying xylazine as a schedule III controlled drug.

SPONSORS: Sen. Gannon, Dist 23; Sen. Abbas, Dist 22; Sen. Birdsell, Dist 19; Sen. Carson, Dist 14; Sen. Rochefort, Dist 1; Sen. McConkey, Dist 3; Rep. L. Walsh, Rock. 15; Rep. Vose, Rock. 5; Rep. Roy, Rock. 31; Rep. Rhodes, Ches. 17

COMMITTEE: Judiciary

ANALYSIS

This bill classifies xylazine as a schedule III controlled drug.

Explanation: Matter added to current law appears in ***bold italics***.
Matter removed from current law appears ~~[in brackets and struckthrough.]~~
Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.

STATE OF NEW HAMPSHIRE

In the Year of Our Lord Two Thousand Twenty-Six

AN ACT classifying xylazine as a schedule III controlled drug.

Be it Enacted by the Senate and House of Representatives in General Court convened:

1 1 New Section; Controlled Drug Act; Xylazine. Amend RSA 318-B by inserting after section 1-c
2 the following new section:

3 318-B:1-d Xylazine.

4 I. Notwithstanding the provisions of RSA 318-B:1-a, relative to scheduling by rulemaking of
5 the commissioner of the department of health and human services, xylazine shall be scheduled as a
6 schedule III controlled drug.

7 II. Notwithstanding paragraph I, nothing in this section shall prevent any licensed
8 veterinarian, as defined in RSA 332-B:1, from doing any of the following:

9 (a) Dispensing or prescribing for, or administering to, a nonhuman species of a drug
10 containing xylazine that has been approved by the Secretary of Health and Human Services under
11 section 512 of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. section 360b.

12 (b) Dispensing or prescribing for, or administering to, a nonhuman species that is
13 permissible under section 512(a)(4) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. section
14 360b(a)(4).

15 (c) Another use that is approved or permissible under the Federal Food, Drug, and
16 Cosmetic Act.

17 2 Effective Date. This act shall take effect January 1, 2027.

**SB 465-FN- FISCAL NOTE
AS AMENDED BY THE SENATE (AMENDMENT #2026-0842s)**

AN ACT classifying xylazine as a schedule III controlled drug.

FISCAL IMPACT:

Estimated State Impact				
	FY 2026	FY 2027	FY 2028	FY 2029
Revenue	\$0	\$0	\$0	\$0
<i>Revenue Fund</i>	None			
Expenditures*	Indeterminable			
<i>Funding Source</i>	General Fund			
Appropriations*	\$0	\$0	\$0	\$0
<i>Funding Source</i>	None			

***Expenditure = Cost of bill *Appropriation = Authorized funding to cover cost of bill**

Estimated Political Subdivision Impact				
	FY 2026	FY 2027	FY 2028	FY 2029
County Revenue	\$0	\$0	\$0	\$0
County Expenditures	Indeterminable			
Local Revenue	\$0	\$0	\$0	\$0
Local Expenditures	Indeterminable			

METHODOLOGY:

This bill adds, deletes, or modifies a criminal penalty, or changes statute to which there is a penalty for violation. Therefore, this bill may have an impact on the judicial and correctional systems, which could affect prosecution, incarceration, probation, and parole costs, for the state, as well as county and local governments. A summary of such costs can be found at: https://gencourt.state.nh.us/lba/Budget/Fiscal_Notes/JudicialCorrectionalCosts.pdf

AGENCIES CONTACTED:

Judicial Branch, Judicial Council, Department of Justice, Department of Corrections, New Hampshire Association of Counties, and New Hampshire Municipal Association